Pyxis Oncology, Inc. Operating Lease Cost
Pyxis Oncology, Inc. (PYXS) reported Operating Lease Cost of $669.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- Pyxis Oncology, Inc. operating lease, cost for the quarter ending 2026-06-30 was $669.00K, a 2.14% increase year-over-year.
- Pyxis Oncology, Inc. operating lease, cost for the quarter ending 2026-03-31 was $671.00K, a 0.15% decline year-over-year.
- Pyxis Oncology, Inc. operating lease, cost for the quarter ending 2025-12-31 was $663.00K, a 0.00% change year-over-year.
- Pyxis Oncology, Inc. operating lease, cost for the quarter ending 2025-09-30 was $663.00K, a 0.00% change year-over-year.
- Pyxis Oncology, Inc. operating lease, cost for fiscal 2025 was $2.65M, a 0.00% change from fiscal 2024.
- Pyxis Oncology, Inc. operating lease, cost for fiscal 2024 was $2.65M, a 0.49% decline from fiscal 2023.
- Pyxis Oncology, Inc. operating lease, cost for fiscal 2023 was $2.67M, a 34.78% increase from fiscal 2022.
- Pyxis Oncology, Inc. operating lease, cost for fiscal 2022 was $1.98M, a 204.31% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $669.00K 10-Q · filed 2026-08-13 | $1.34M 10-Q · filed 2026-08-13 | $2.00M derived: sum of 3 quarters · filed 2026-08-13 | $2.67M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $671.00K 10-Q · filed 2026-05-14 | $1.33M derived: sum of 2 quarters · filed 2026-05-14 | $2.00M derived: sum of 3 quarters · filed 2026-05-14 | $2.65M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.33M derived: sum of 2 quarters · filed 2026-03-23 | $1.98M derived: sum of 3 quarters · filed 2026-08-13 | $2.65M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $663.00K 10-Q · filed 2025-11-03 | $1.32M derived: sum of 2 quarters · filed 2026-08-13 | $1.99M 10-Q · filed 2025-11-03 | $2.65M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $655.00K 10-Q · filed 2026-08-13 | $1.33M 10-Q · filed 2026-08-13 | $1.99M derived: sum of 3 quarters · filed 2026-08-13 | $2.65M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $672.00K 10-Q · filed 2026-05-14 | $1.33M derived: sum of 2 quarters · filed 2026-05-14 | $2.00M derived: sum of 3 quarters · filed 2026-05-14 | $2.66M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.33M derived: sum of 2 quarters · filed 2026-03-23 | $1.99M derived: sum of 3 quarters · filed 2026-03-23 | $2.65M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $663.00K 10-Q · filed 2025-11-03 | $1.33M derived: sum of 2 quarters · filed 2025-11-03 | $1.99M 10-Q · filed 2025-11-03 | $2.66M derived: sum of 4 quarters · filed 2025-11-03 | |
| 2024-06-30 | $663.00K 10-Q · filed 2025-08-14 | $1.33M 10-Q · filed 2025-08-14 | $2.00M derived: sum of 3 quarters · filed 2025-08-14 | $2.67M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $663.00K 10-Q · filed 2025-05-15 | $700.00K 10-Q · filed 2024-05-14 | $1.33M derived: sum of 2 quarters · filed 2025-05-15 | $2.01M derived: sum of 3 quarters · filed 2025-05-15 | $2.67M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $669.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.35M derived: sum of 2 quarters · filed 2025-03-18 | $2.01M derived: sum of 3 quarters · filed 2025-03-18 | $2.67M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $678.00K 10-Q · filed 2024-11-12 | $1.34M derived: sum of 2 quarters · filed 2024-11-12 | $2.00M 10-Q · filed 2024-11-12 | $2.63M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $663.00K 10-Q · filed 2024-08-14 | $1.32M 10-Q · filed 2024-08-14 | $1.95M derived: sum of 3 quarters · filed 2024-08-14 | $2.61M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $700.00K 10-Q · filed 2024-05-14 | $656.00K 10-Q · filed 2023-05-11 | $1.29M derived: sum of 2 quarters · filed 2024-05-14 | $1.95M derived: sum of 3 quarters · filed 2024-05-14 | $2.68M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $586.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.25M derived: sum of 2 quarters · filed 2024-03-21 | $1.98M derived: sum of 3 quarters · filed 2024-03-21 | $1.98M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $660.00K 10-Q · filed 2023-11-07 | $1.39M derived: sum of 2 quarters · filed 2023-11-07 | $1.39M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $732.00K 10-Q · filed 2023-08-11 | $732.00K 10-Q · filed 2023-08-11 | |||
| 2021-12-31 | $650.00K 10-K · filed 2023-03-22 | ||||
| 2020-12-31 | $497.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |